Skip to main content
. Author manuscript; available in PMC: 2019 Dec 30.
Published in final edited form as: Cell Rep. 2019 Nov 26;29(9):2672–2688.e7. doi: 10.1016/j.celrep.2019.10.110

Figure 7. TRA2β Plays a Role in Metastasis In Vivo in a TNBC Mouse Model and in Breast Cancer Patients.

Figure 7.

(A) CTLsh or TRA2βsh2MDA-MB231 cells are injected into the mammary fat pad of NSG mice; primary tumors and metastasis are monitored by bioluminescence imaging.

(B) Bioluminescence detection of primary tumors and metastasis in mice injected with CTLsh or TRA2βsh2 MDA-MB231 cells ± DOX at 8 weeks post-injection.

(C) Representative H&E lung and liver sections of mice injected with TRA2βsh2 MDA-MB231 cells ± DOX (scale bar: 1 mm). Metastatic areas are circled in blue.

(D) Quantification of metastasis burden in mice injected with CTLsh or TRA2βsh2 MDA-MB231 cells ± DOX (n ≥ 4; t test, *p < 0.01, **p < 0.001, n.s., not significant).

(E and F) Correlation between TRA2β expression and overall survival (E) or distant metastasis-free survival (F) in cohorts of breast cancer patients stratified by TRA2β levels. Cohort size, dataset, and probe ID, and corrected p value (log-rank test) are indicated.

See also Figure S7.